Gradient Investments LLC Has $376,000 Stake in Eli Lilly and Company (NYSE:LLY)

Gradient Investments LLC trimmed its stake in Eli Lilly and Company (NYSE:LLYGet Rating) by 95.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,161 shares of the company’s stock after selling 22,018 shares during the period. Gradient Investments LLC’s holdings in Eli Lilly and were worth $376,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in Eli Lilly and by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock worth $20,183,695,000 after purchasing an additional 1,219,424 shares during the last quarter. State Street Corp boosted its position in shares of Eli Lilly and by 2.5% during the 4th quarter. State Street Corp now owns 33,929,864 shares of the company’s stock valued at $9,372,107,000 after acquiring an additional 813,983 shares in the last quarter. Capital World Investors boosted its position in shares of Eli Lilly and by 17.0% during the 1st quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock valued at $6,402,838,000 after acquiring an additional 3,242,548 shares in the last quarter. Capital International Investors boosted its position in shares of Eli Lilly and by 30.5% during the 1st quarter. Capital International Investors now owns 8,839,241 shares of the company’s stock valued at $2,532,024,000 after acquiring an additional 2,063,557 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Eli Lilly and during the 4th quarter valued at about $2,213,765,000. 82.45% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on LLY shares. SVB Leerink started coverage on shares of Eli Lilly and in a research report on Monday, May 23rd. They set an “outperform” rating and a $341.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. Morgan Stanley lifted their target price on shares of Eli Lilly and from $395.00 to $412.00 and gave the company an “overweight” rating in a research report on Wednesday, September 7th. BMO Capital Markets lifted their price target on shares of Eli Lilly and from $369.00 to $396.00 and gave the company an “outperform” rating in a report on Tuesday, September 6th. Finally, Citigroup lifted their price target on shares of Eli Lilly and from $285.00 to $370.00 in a report on Thursday, August 25th. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $330.44.

Eli Lilly and Trading Down 1.2 %

Shares of NYSE LLY opened at $305.09 on Tuesday. Eli Lilly and Company has a 1-year low of $220.20 and a 1-year high of $335.33. The company has a market cap of $289.89 billion, a PE ratio of 48.66, a P/E/G ratio of 2.00 and a beta of 0.38. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 1.70. The company has a 50-day moving average of $316.13 and a two-hundred day moving average of $303.88.

Eli Lilly and (NYSE:LLYGet Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.86 by ($0.61). The business had revenue of $6.49 billion for the quarter, compared to the consensus estimate of $6.85 billion. Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The company’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the firm earned $1.87 earnings per share. As a group, equities analysts expect that Eli Lilly and Company will post 7.97 earnings per share for the current fiscal year.

Eli Lilly and Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 9th. Investors of record on Monday, August 15th were paid a dividend of $0.98 per share. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date was Friday, August 12th. Eli Lilly and’s dividend payout ratio (DPR) is 62.52%.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 215,000 shares of the business’s stock in a transaction that occurred on Friday, June 24th. The shares were sold at an average price of $324.31, for a total transaction of $69,726,650.00. Following the completion of the sale, the insider now directly owns 104,203,810 shares of the company’s stock, valued at $33,794,337,621.10. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Jackson P. Tai acquired 656 shares of the firm’s stock in a transaction that occurred on Friday, August 12th. The stock was purchased at an average price of $304.19 per share, for a total transaction of $199,548.64. Following the completion of the acquisition, the director now owns 62,857 shares in the company, valued at $19,120,470.83. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the business’s stock in a transaction that occurred on Friday, June 24th. The shares were sold at an average price of $324.31, for a total transaction of $69,726,650.00. Following the transaction, the insider now owns 104,203,810 shares of the company’s stock, valued at approximately $33,794,337,621.10. The disclosure for this sale can be found here. Insiders sold a total of 753,125 shares of company stock valued at $242,744,201 over the last ninety days. Insiders own 0.12% of the company’s stock.

Eli Lilly and Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.